The Insulin-Like Growth Factor Axis: A New Player in Gestational Diabetes Mellitus?

Retnakaran, Ravi

doi:10.2337/dbi16-0048

Cited by 15 publications

(11 citation statements)

References 22 publications

(26 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…IGF‐I deficiency could lead to insulin insensitivity. IGF‐I and/or IGFBPs have been associated with GDM and preeclampsia . IGF‐I circulate in the serum in complex with IGFBP‐3 or IGFBP‐5, and an acid‐labile subunit (ALS), the ternary complex could inhibit IGF actions and release, and prolong their half‐life .…”

Section: Discussionmentioning

confidence: 99%

Comparative Proteomics Analysis of Serum Proteins in Gestational Diabetes during Early and Middle Stages of Pregnancy

Shen

Zhao

Chen

et al. 2019

Proteomics Clinical Apps

View full text Add to dashboard Cite

Purpose This study is designed to screen serum proteins that may serve as biomarkers for gestational diabetes mellitus (GDM), and clarify the mechanisms of disease. Experimental Design By using isobaric tags for relative and absolute quantitation proteomics analysis, serum proteins levels were quantified in pregnant women who subsequently developed GDM (12–16 weeks), GDM patients (24–28 weeks), and their corresponding controls. The strategy of mixing samples is used in proteomic analysis. Results Thirty‐one and 27 differentially expressed proteins are identified in the serum of pregnant women with developed GDM at 12–16 weeks and GDM patients during 24–28 weeks, respectively. Thirty eight and 28 proteins are identified in 24–28 weeks versus 12–16 weeks controls (24/12 CTR group), and 24–28 weeks GDM patients versus 12–16 weeks women with subsequently developed GDM (24/12 GDM group), respectively. Most of these proteins in the case and control subjects are associated with diabetes and maternal and perinatal short‐ and long‐term complications. Conclusions and Clinical Relevance The results highlight the roles of complement system and the blood clotting cascade in the pathogenesis of GDM. Differentially expressed proteins may serve as potential biomarkers for GDM prediction and diagnosis in the future.

show abstract

Section: Discussionmentioning

confidence: 99%

Comparative Proteomics Analysis of Serum Proteins in Gestational Diabetes during Early and Middle Stages of Pregnancy

Shen

Zhao

Chen

et al. 2019

Proteomics Clinical Apps

View full text Add to dashboard Cite

show abstract

“…In addition, each of these features has been shown to be present as early as 3 months after delivery, suggesting that women with GDM may experience long-term exposure to this enhanced risk factor profile [3,[26][27][28]. Further supporting this chronicity is a growing body of evidence showing that women who develop GDM have cardiometabolic abnormalities prior to their pregnancy [29,30]. Taken together, these data support the emerging concept that women who develop GDM actually have a chronic metabolic disorder that comes to clinical attention during gestation, although it exists before, during and after the pregnancy [30].…”

Section: Studymentioning

confidence: 99%

“…Further supporting this chronicity is a growing body of evidence showing that women who develop GDM have cardiometabolic abnormalities prior to their pregnancy [29,30]. Taken together, these data support the emerging concept that women who develop GDM actually have a chronic metabolic disorder that comes to clinical attention during gestation, although it exists before, during and after the pregnancy [30]. In this way, the diagnosis of GDM may be seen as identifying women who have a longstanding, high-risk cardiometabolic phenotype that would otherwise escape clinical detection during the relative youth of their childbearing years, if not for the glucose tolerance screening that they undergo in pregnancy (which is the only situation in practice in which population testing for diabetes is routinely performed).…”

Section: Studymentioning

confidence: 99%

Gestational diabetes and the risk of cardiovascular disease in women: a systematic review and meta-analysis

2019

Self Cite

View full text Add to dashboard Cite

Aims/hypothesis Women who develop gestational diabetes mellitus (GDM) have an elevated lifetime risk of type 2 diabetes mellitus. Recently, a series of studies has suggested that women with GDM also have an increased risk of cardiovascular disease (CVD). However, it is unclear if this risk is dependent upon the intercurrent development of type 2 diabetes. Thus, we conducted a systematic review and meta-analysis to evaluate the impact of GDM on future risk of incident CVD and to ascertain the role of type 2 diabetes in this regard. Methods We systematically searched the PubMed and EMBASE databases for observational studies that evaluated the association of GDM with subsequent CVD, with publication between 1 January 1950 and 30 August 2018. Two independent reviewers extracted data and the analysis was performed in accordance with Meta-analysis of Observational Studies in Epidemiology (MOOSE) guidelines. RRs were calculated using a random-effects model to assess the predictive value of GDM for future cardiovascular events. To evaluate whether incident type 2 diabetes in the GDM population influenced the association with CVD, we used meta-regression models followed by sensitivity analyses restricted to women who did not develop type 2 diabetes during follow-up. Results A pooled analysis of nine studies yielded data from 5,390,591 women (101,424 cardiovascular events). Compared with those who did not have GDM, women with GDM had a twofold higher risk of future cardiovascular events (RR 1.98 [95% CI 1.57, 2.50]). Meta-regression analysis showed that the rates of incident type 2 diabetes across the studies did not affect this risk (p = 0.34). Moreover, when restricted to women who did not develop type 2 diabetes, GDM remained associated with a 56% higher risk of future cardiovascular events (RR 1.56 [95% CI 1.04, 2.32]). GDM conferred a 2.3-fold increased risk of cardiovascular events in the first decade postpartum (RR 2.31 [95% CI 1.57, 3.39]). Conclusions/interpretation The diagnosis of GDM identifies young women who have a twofold higher risk of cardiovascular events postpartum compared with their peers. This risk is not dependent upon intercurrent type 2 diabetes and is apparent within the first decade after pregnancy. Thus, even without progressing to type 2 diabetes, women with GDM comprise an at-risk population for CVD and hence a potential opportunity for early risk factor surveillance and risk modification.

show abstract

“… 28 , 35 , 36 Second, the measurement of cardiometabolic biomarkers in 1st trimester (such as glycemic and lipid measures, adiponectin, C-reactive protein, tissue plasminogen activator antigen, and insulin-like growth factor binding protein-2) can predict the subsequent development of GDM later in pregnancy. 37 Third, it has been shown that the amniotic fluid of women who go on to develop GDM already shows metabolic changes in 1st trimester and fetal overgrowth can occur before the diagnosis of GDM. 38 , 39 Finally, and most importantly, cardiometabolic differences between women who go on to develop GDM and those who do not are already present even before the pregnancy.…”

Section: Future Health Implications Of Gdm After Pregnancymentioning

confidence: 99%

The Insulin-Like Growth Factor Axis: A New Player in Gestational Diabetes Mellitus?

Cited by 15 publications

References 22 publications

Comparative Proteomics Analysis of Serum Proteins in Gestational Diabetes during Early and Middle Stages of Pregnancy

Comparative Proteomics Analysis of Serum Proteins in Gestational Diabetes during Early and Middle Stages of Pregnancy

Gestational diabetes and the risk of cardiovascular disease in women: a systematic review and meta-analysis

The life course perspective of gestational diabetes: An opportunity for the prevention of diabetes and heart disease in women

Contact Info

Product

Resources

About